Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
Multiple Myeloma
About this trial
This is an interventional treatment trial for Multiple Myeloma
Eligibility Criteria
Inclusion Criteria: Diagnosis of multiple myeloma in first or second complete or partial remission >= 4 weeks since last cycle of chemotherapy (thalidomide, dexamethasone, and Velcade were not considered prior chemotherapy for the purpose of this study) Recovered from all acute toxic effects of prior chemotherapy Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 White Blood Cell count (WBC) > 2.5*10^9/L Absolute polymorphonuclear leukocytes (PMN) count > 1.5*10^9/L Platelet (PLT) > 100*10^9/L Serum creatinine <=2.2 mg/dL Cardiac and pulmonary status sufficient to undergo apheresis and transplantation Negative for HIV Exclusion Criteria): Failed previous stem cell collection Previous stem cell transplantation Brain metastases or myelomatous meningitis Radiation to ≥ 50% of the pelvis Abnormal electrocardiogram (ECG) with rhythm disturbance (ventricular arrhythmias) or other conduction abnormality Received bone-seeking radionuclides (e.g. holmium) A residual acute medical condition resulting from prior chemotherapy
Sites / Locations
- City of Hope Samaritan Bone Marrow Transplant Program
- Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
- City of Hope National Medical Center
- Cedars-Sinai
- University of California
- Rocky Mountain Cancer Center
- Yale University School of Medicine
- University of Florida
- H. Lee Moffitt Cancer Center and Research Institute
- Emory University
- Loyola University Medical Center
- Indiana Blood and Marrow Transplantation Center
- University of Iowa Hosptials and Clinics
- Fairview-University Medical Center, University of Minnesota
- Mayo Clinic
- Kansas City Cancer Center
- Washington University School of Medicine, Division of Bone Marrow Transplantation and Leukemia
- The Cancer Center at Hackensack University Medical Center
- Roswell Park Cancer Institute
- St. Vincent's Comprehensive Cancer Center
- New York Hospital
- Memorial Sloan Kettering
- University of Rochester Medical Center
- Duke University Medical Center
- Case Western Reserve University
- Cleveland Clinic Foundation
- Ohio State University
- Oregon Health & Science University
- Hospital of the University of Pennsylvania
- Thomas Jefferson University
- The University of Texas MD Anderson Cancer Center
- Wilford Hall Medical Center
- Texas Transplant Institute
- University of Texas Health Science Center
- Utah Blood and Marrow Transplant Program, University of Utah
- Virginia Commonwealth University
- Fred Hutchinson Cancer Research Center
- Vancouver General Hospital
- Universitätsklinikum Heidelberg,
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
G-CSF plus plerixafor
G-CSF plus placebo